newsfilter
← Latest News
GlobeNewswire·

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD® U.S. net sales